The association between antibody levels before and after 7-valent pneumococcal conjugate vaccine immunization and subsequent pneumococcal infection in chronic arthritis patients

AbstractWe describe here changes in the bacterial causes of pleural empyema before and after implementation of the 13-valent pneumococcal conjugate vaccine (PCV13) program in France (2009–2017). For 220 (39.3%) of 560 children, a bacterial cause was found. The frequency of pneumococcal infection decreased during the study from 79.1% in 2009 to 36.4% in 2017 (P < .001). Group A streptococcus is now the leading cause of documented empyema (45.5%).

Download Full-text

Pneumococcal Nasopharyngeal Carriage following Reduced Doses of a 7-Valent Pneumococcal Conjugate Vaccine and a 23-Valent Pneumococcal Polysaccharide Vaccine Booster

Clinical and Vaccine Immunology ◽

10.1128/cvi.00117-10 ◽

2010 ◽

Vol 17 (12) ◽

pp. 1970-1976 ◽

Cited By ~ 48

Author(s):

F. M. Russell ◽

J. R. Carapetis ◽

C. Satzke ◽

L. Tikoduadua ◽

L. Waqatakirewa ◽

...

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Polysaccharide Vaccine ◽

Dose Effect ◽

Pneumococcal Polysaccharide Vaccine ◽

Pneumococcal Carriage ◽

Primary Series ◽

Vaccine Type ◽

Vaccine Booster ◽

Antibody Levels

ABSTRACT This study was conducted to evaluate the effect of a reduced-dose 7-valent pneumococcal conjugate vaccine (PCV) primary series followed by a 23-valent pneumococcal polysaccharide vaccine (23vPPS) booster on nasopharyngeal (NP) pneumococcal carriage. For this purpose, Fijian infants aged 6 weeks were randomized to receive 0, 1, 2, or 3 PCV doses. Within each group, half received 23vPPS at 12 months. NP swabs were taken at 6, 9, 12, and 17 months and were cultured for Streptococcus pneumoniae. Isolates were serotyped by multiplex PCR and a reverse line blot assay. There were no significant differences in PCV vaccine type (VT) carriage between the 3- and 2-dose groups at 12 months. NP VT carriage was significantly higher (P, <0.01) in the unvaccinated group than in the 3-dose group at the age of 9 months. There appeared to be a PCV dose effect in the cumulative proportion of infants carrying the VT, with less VT carriage occurring with more doses of PCV. Non-PCV serotype (NVT) carriage rates were similar for all PCV groups. When groups were pooled by receipt or nonreceipt of 23vPPS at 12 months, there were no differences in pneumococcal, VT, or NVT carriage rates between the 2 groups at the age of 17 months. In conclusion, there appeared to be a PCV dose effect on VT carriage, with less VT carriage occurring with more doses of PCV. By the age of 17 months, NVT carriage rates were similar for all groups. 23vPPS had no impact on carriage, despite the substantial boosts in antibody levels.

Download Full-text

Incidence of Invasive Pneumococcal Disease among Individuals with Sickle Cell Disease before and after the Introduction of the Pneumococcal Conjugate Vaccine

Clinical Infectious Diseases ◽

10.1086/516781 ◽

2007 ◽

Vol 44 (11) ◽

pp. 1428-1433 ◽

Cited By ~ 142

Author(s):

N. B. Halasa ◽

S. M. Shankar ◽

T. R. Talbot ◽

P. G. Arbogast ◽

E. F. Mitchel ◽

...

Keyword(s):

Sickle Cell Disease ◽

Conjugate Vaccine ◽

Invasive Pneumococcal Disease ◽

Sickle Cell ◽

Pneumococcal Conjugate Vaccine ◽

Pneumococcal Disease ◽

Cell Disease ◽

Before And After

Download Full-text

Assignment of Weight-Based Immunoglobulin G1 (IgG1) and IgG2 Units in Antipneumococcal Reference Serum Lot 89-S(F) for Pneumococcal Polysaccharide Serotypes 1, 4, 5, 7F, 9V, and 18C

Clinical and Diagnostic Laboratory Immunology ◽

10.1128/cdli.12.1.218-223.2005 ◽

2005 ◽

Vol 12 (1) ◽

pp. 218-223 ◽

Cited By ~ 5

Author(s):

Daniel J. Sikkema ◽

Nancy A. Ziembiec ◽

Thomas R. Jones ◽

Stephen W. Hildreth ◽

Dace V. Madore ◽

...

Keyword(s):

Streptococcus Pneumoniae ◽

Immune Responses ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Pneumococcal Disease ◽

Pneumococcal Infection ◽

Capsular Polysaccharides ◽

Standardization Method ◽

Igg2 Antibody ◽

Reference Serum

ABSTRACT Weight-based assignments for immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to Streptococcus pneumoniae capsular polysaccharides (PnPs) in antipneumococcal standard reference serum lot 89-S (lot 89-S), also known as lot 89-SF, have been determined for serotypes 1, 4, 5, 7F, 9V, and 18C. This extends the usefulness of lot 89-S beyond the IgG1 and IgG2 subclass assignments for serotypes 3, 6B, 14, 19F, and 23F made previously (A. Soininen, H. Kayhty, I. Seppala, and T. Wuorimaa, Clin. Diagn. Lab. Immunol. 5:561-566, 1998) to cover 11 major serotypes associated with the highest percentage of pneumococcal disease worldwide. A method of equivalence of absorbances in enzyme immunosorbent assays was used to determine the IgG1 and IgG2 antibody concentrations for the additional serotypes in lot 89-S, based on the subclass values previously assigned for PnPs serotypes 6B, 14, and 23F. This cross-standardization method assures consistency with previous antibody assignments in that reference serum. The newly assigned subclass values for serotype 9V, and previously assigned values for serotype 14, were used to quantitate PnPs antibodies in sera from adult and pediatric subjects immunized with a pneumococcal conjugate vaccine. There was a predominance of IgG1 anti-PnPs antibodies in pediatric sera and IgG2 anti-PnPs antibodies in the adult sera. The IgG1 and IgG2 subclass assignments for the 11 PnPs serotypes in antipneumococcal standard reference serum lot 89-S are useful for quantitating and characterizing immune responses to pneumococcal infection and vaccination regimens.

Download Full-text

964Seroepidemiology of Pediatric Pneumococcal Colonization and Infection Before and After 13-valent Pneumococcal Conjugate Vaccine (PCV13)

Open Forum Infectious Diseases ◽

10.1093/ofid/ofu052.672 ◽

2014 ◽

Vol 1 (suppl_1) ◽

pp. S280-S281

Author(s):

Douglas Swanson ◽

Christopher Harrison ◽

R. Scott Duncan ◽

Chris Paap ◽

Laura Puzniak

Keyword(s):

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Before And After ◽

Pneumococcal Colonization

Download Full-text

Peer Review #1 of "Temporal changes in nasopharyngeal carriage of Streptococcus pneumoniae serotype 1 genotypes in healthy Gambians before and after the 7-valent pneumococcal conjugate vaccine (v0.1)"

10.7287/peerj.903v0.1/reviews/1 ◽

2015 ◽

Author(s):

S Obaro

Keyword(s):

Streptococcus Pneumoniae ◽

Peer Review ◽

Conjugate Vaccine ◽

Pneumococcal Conjugate Vaccine ◽

Temporal Changes ◽

Nasopharyngeal Carriage ◽

Before And After ◽

Serotype 1

Download Full-text

Vaccination rates and adherence in premature infants before and after pneumococcal conjugate vaccine schedule change for term infants – A claims database analysis in Germany

Vaccine ◽

10.1016/j.vaccine.2021.11.002 ◽

2021 ◽

Author(s):

Maren Laurenz ◽

Christof von Eiff ◽

Kathrin Borchert ◽

Christian Jacob ◽

Karolin Seidel ◽

...

Keyword(s):

Conjugate Vaccine ◽

Premature Infants ◽

Pneumococcal Conjugate Vaccine ◽

Database Analysis ◽

Term Infants ◽

Claims Database ◽

Vaccination Rates ◽

Vaccine Schedule ◽

Before And After ◽

Schedule Change

Download Full-text

Pneumococcal Conjugate Vaccine impact assessment in Bangladesh

Gates Open Research ◽

10.12688/gatesopenres.12805.1 ◽

2018 ◽

Vol 2 ◽

pp. 21 ◽

Cited By ~ 5

Author(s):

Abdullah H. Baqui ◽

Eric D. McCollum ◽

Samir K. Saha ◽

Arun K. Roy ◽

Nabidul H. Chowdhury ◽

...

Keyword(s):

Conjugate Vaccine ◽

Study Design ◽

Pneumococcal Conjugate Vaccine ◽

Case Control Study ◽

Case Control ◽

Incident Case ◽

Vaccine Type ◽

Before And After ◽

The Impact ◽

Control Study

The study examines the impact of the introduction of 10-valent Pneumococcal Conjugate Vaccine (PCV10) into Bangladesh’s national vaccine program. PCV10 is administered to children under 1 year-old; the scheduled ages of administration are at 6, 10, and 18 weeks. The study is conducted in ~770,000 population containing ~90,000 <5 children in Sylhet, Bangladesh and has five objectives: 1) To collect data on community-based pre-PCV incidence rates of invasive pneumococcal diseases (IPD) in 0-59 month-old children in Sylhet, Bangladesh; 2) To evaluate the effectiveness of PCV10 introduction on Vaccine Type (VT) IPD in 3-59 month-old children using an incident case-control study design. Secondary aims include measuring the effects of PCV10 introduction on all IPD in 3-59 month-old children using case-control study design, and quantifying the emergence of Non Vaccine Type IPD; 3) To evaluate the effectiveness of PCV10 introduction on chest radiograph-confirmed pneumonia in children 3-35 months old using incident case-control study design. We will estimate the incidence trend of clinical and radiologically-confirmed pneumonia in 3-35 month-old children in the study area before and after introduction of PCV10; 4) To determine the feasibility and utility of lung ultrasound for the diagnosis of pediatric pneumonia in a large sample of children in a resource-limited setting. We will also evaluate the effectiveness of PCV10 introduction on ultrasound-confirmed pneumonia in 3-35 month-old children using an incident case-control design and to examine the incidence trend of ultrasound-confirmed pneumonia in 3-35 month-old children in the study area before and after PCV10 introduction; and 5) To determine the direct and indirect effects of vaccination status on nasopharyngeal colonization on VT pneumococci among children with pneumonia. This paper presents the methodology. The study will allow us to conduct a comprehensive and robust assessment of the impact of national introduction of PCV10 on pneumococcal disease in Bangladesh.

Download Full-text